The veterinary technology sector is bursting with too many platforms, too little interoperability, and a growing recognition that the most valuable feline clinical data is the kind collected between visits.

Two companies working that gap in ways directly relevant to cats are Healthy Pet Connect (HPC) and Voyce, whose partnership is worth watching.

HPC, founded by Wisconsin-based veterinarian Dr. Ken Lambrecht, is a remote patient monitoring platform built around chronic disease management and preventive care.

Voyce, co-founded by veterinarian Dr. Amanda Landis-Hanna, is developing a biometric wearable sensor (heart rate, respiratory rate, heart rate variability, and crucially, blood pressure) designed explicitly for the veterinary channel.

Lambrecht identifies Voyce as one of the most significant incoming data partners for his platform, specifically for its potential to deliver something that has long eluded feline medicine.

"One particular one is Voyce," he said, "that will even be able to do remote blood pressure in cats - a complete game changing home and clinic data point."

Landis-Hanna also highlights why this matters for cats specifically: blood pressure readings taken at the clinic are routinely compromised by stress. "We don't really know what a blood pressure in a cat is in a non-sedated state," she said.

"If you give gabapentin to help the cat relax and it alters their blood pressure - all of those things have impacted the cat's blood pressure. So being able to get blood pressures at home in our patients is going to be revolutionary."

The clinical implications are significant. Cats with hypertension are typically monitored in the clinic, where stress (also known as ‘white coat syndrome’) can significantly affect readings, making it genuinely difficult to assess whether treatment is working.

Home-based biometric data would allow for two separate normals - clinic and home - and enable far more accurate medication management.

Voyce's commercial model is veterinary-first: the sensor is bought by the vet and leased to the client, with Voyce retaining data ownership to refine algorithms and build population-level norms.

Landis-Hanna frames this explicitly as a feature rather than a limitation. "The dumbest that the sensor will ever be is day one," she said, "but the sensor gets smarter about the patient" over time.

Data is tiered by user: pet parents receive averaged, less granular readings; vets get pre-processed clinical data; CROs receive raw CSV files for trial use. This structure is designed to serve pharmaceutical R&D - a market Landis-Hanna believes will find feline data disproportionately valuable, precisely because so little validated feline data is available.

Both Lambrecht and Landis-Hanna are candid about the friction in the current landscape. "It seems exactly the same" as the closed-loop human tracker era of the late 1990s, Lambrecht said, when asked whether veterinary wearables risk becoming data silos.

His answer is API-driven integration: HPC is currently working on five API connections with AI scribes to make its dashboard accessible within existing clinic workflows.

Lambrecht's vision is a unified home-and-clinic dashboard: weight trends, food intake, activity data, and biometric vitals alongside lab results, all visible in the exam room.

"I would be able to see a five-year weight trend from clinic weights and integrate it with five to ten home weights," he said. "All of those pop up in the exam room on a dashboard - and I can say, look, we're doing great here, or we need to make changes."

For animal health companies and large pet corporations, the signal here is structural: the most defensible position in the feline remote monitoring space is not the sensor or the platform in isolation, but the validated data architecture that connects both to the veterinary workflow.

While consumer-facing trackers like Moggie or Tractive are gathering volume; what Voyce and HPC are building is clinical-grade data with research utility.

As Lambrecht put it: "Shared validated dashboards are the future." The cat space, chronically underserved in both device design and clinical data, may get there faster than anyone expects.